Bruton's tyrosine kinase inhibitor - Pharmacyclics

Drug Profile

Bruton's tyrosine kinase inhibitor - Pharmacyclics

Alternative Names: BTK Inhibitor - Pharmacyclics

Latest Information Update: 28 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacyclics
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Inflammation

Most Recent Events

  • 26 May 2015 Pharmacyclics has been acquired by AbbVie
  • 31 Jan 2014 Preclinical trials in Autoimmune disorders in USA (PO)
  • 31 Jan 2014 Preclinical trials in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top